NBIX News

Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patients

Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities

Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026

Form 8-K

Motive revela el futuro de las operaciones físicas en Vision 26: Una nueva era de hardware integrado e innovaciones de IA

Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules

Form 8-K

Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics

Pharmazz, Inc. Appoints Ajay Bansal as Chief Financial Officer

4basebio Announces Appointment of Chief Financial Officer and Board Changes